A protein chimera including PspA in fusion with PotD is protective against invasive pneumococcal infection and reduces nasopharyngeal colonization in mice. Issue 38 (12th September 2017)

• Record Type: Journal Article
• Authors: Converso, T.R.; Goulart, C.; Darrieux, M.; Leite, L.C.C.
• Is Part Of: Vaccine. Volume 35:Issue 38(2017)
• Page Start: 5140
• Page End: 5147
• Publication Date: 2017-09-12
• Subjects: Chimeric pneumococcal proteins -- Protein vaccine -- Polyamine transporter D -- PspA -- Streptococcus pneumoniae; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.08.010
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Despite the success of the available polysaccharide-based vaccines against Streptococcus pneumoniae in preventing invasive diseases, this bacterium remains a major cause of death in many parts of the world. New vaccine strategies are needed in order to increase protection. Thus, the utilization of fusion proteins is being investigated as an alternative to the current formulations. In the present work, we demonstrate that a chimeric protein, composed of PspA and PotD in fusion is able to maintain the protective characteristics of both parental proteins, providing protection against systemic infection while reducing nasal colonization. The hybrid was not able to improve the response against invasive disease elicited by PspA alone, but the inclusion of PotD was able to reduce colonization, an effect never observed using subcutaneous immunization with PspA. The mechanisms underlying the protective efficacy of the rPspA-PotD hybrid protein were investigated, revealing the production of antibodies with an increased binding capacity to pneumococcal strains of diverse serotypes and genetic backgrounds, enhanced opsonophagocytosis, and secretion of IL-17 by splenocytes. These findings reinforce the use of chimeric proteins based on surface antigens as an effective strategy against pneumococcal infections.